Clinical trial
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
NCT00004154 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004154 |
|---|---|
| Title | Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer |
| Official title | Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug, Other |
| Interventions | Fenretinide, Placebo |
| Enrollment | 111 |
| Start date | Jul 30, 1998 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 8, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: